前のページに戻る この文献は全文を取り寄せることができます
JDreamⅢ複写サービスから文献全文の複写（冊子体のコピー）をお申込みできます。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
既に、G-Searchデータベースサービスまたは、JDreamⅢのIDをお持ちの方
JDreamⅢ複写サービス
文献複写のお申込み
JDreamⅢ複写サービスのご利用が初めての方
学術文献の全文複写をお取寄せ
JDreamⅢ複写サービスのご案内
取り寄せる文献のタイトルと詳細
文献
J-GLOBAL ID：202002215690933497   整理番号：20A2344581

エフェクターと制御性T細胞間のPD-1発現バランスはPD-1遮断療法の臨床的有効性を予測する【JST・京大機械翻訳】

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
著者 (36件)：
Kumagai Shogo
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Kumagai Shogo
(Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
, 
Togashi Yosuke
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Kamada Takahiro
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Kamada Takahiro
(Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
, 
Sugiyama Eri
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Sugiyama Eri
(Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
, 
Nishinakamura Hitomi
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Takeuchi Yoshiko
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Vitaly Kochin
(Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
, 
Itahashi Kota
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Maeda Yuka
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Matsui Shigeyuki
(Department of Biostatics, Nagoya University Graduate School of Medicine, Nagoya, Japan)
, 
Shibahara Takuma
(Research and Development Group, Hitachi Ltd., Tokyo, Japan)
, 
Yamashita Yasuho
(Research and Development Group, Hitachi Ltd., Tokyo, Japan)
, 
Irie Takuma
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Tsuge Ayaka
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Tsuge Ayaka
(Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)
, 
Fukuoka Shota
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Kawazoe Akihito
(Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan)
, 
Udagawa Hibiki
(Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan)
, 
Kirita Keisuke
(Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan)
, 
Aokage Keiju
(Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan)
, 
Ishii Genichiro
(Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan)
, 
Kuwata Takeshi
(Pathology and Clinical Laboratories, National Cancer Center Hospital East, Chiba, Japan)
, 
Nakama Kenta
(Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan)
, 
Kawazu Masahito
(Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan)
, 
Ueno Toshihide
(Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan)
, 
Yamazaki Naoya
(Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan)
, 
Goto Koichi
(Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan)
, 
Tsuboi Masahiro
(Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan)
, 
Mano Hiroyuki
(Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan)
, 
Doi Toshihiko
(Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan)
, 
Shitara Kohei
(Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan)
, 
Nishikawa Hiroyoshi
(Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Chiba, Japan)
, 
Nishikawa Hiroyoshi
(Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan)

資料名：
Nature Immunology  (Nature Immunology)

巻： 21  号： 11  ページ： 1346-1358  発行年： 2020年 
JST資料番号： W1330A  ISSN： 1529-2908  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)
JDreamⅢ複写サービスとは
JDreamⅢ複写サービスは、学術文献の全文を複写（コピー）して取り寄せできる有料サービスです。インターネットに公開されていない文献や、図書館に収録されていない文献の全文を、オンラインで取り寄せることができます。J-GLOBALの整理番号にも対応しているので、申し込みも簡単にできます。全文の複写（コピー）は郵送またはFAXでお送りします

※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。

Copyright (c) 2009 Japan Science and Technology Agency. All Rights Reserved

TOP

BOTTOM